GSK to take 10% stake in Germany’s CureVac for $163 million

GSK to take 10% stake in Germany’s CureVac for $163 million

Britain’s GSK said on Monday it would buy a 10% stake in Germany’s CureVac for invest $163 million, and launch a collaboration to develop up to five mRNA-based vaccines with technology already being used by the biotech company to develop a COVID-19 vaccine. CureVac’s existing COVID-19 mRNA and rabies vaccines research programmes are not included in the deal, the companies said.

Clara
Clara
Top in Business
Get the App